H. Lundbeck AS Ordinary Shares - Class B
HLUN B: XCSE (DNK)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|.> | LOCK|z@ | LOCK|Lwy%$$Z |
Lundbeck Earnings: Amid Approaching Patent Cliff, Lundbeck Makes Unsolicited Bid for Avadel
Lundbeck reported total revenue of DKK 18.5 billion in the first nine months of 2025, up 14% year over year at constant exchange rates. On Nov. 14, Lundbeck made an unsolicited bid of up to $2.25 billion for Avadel Pharmaceuticals, potentially upending Avadel's existing deal with Alkermes.
